文献速递炎症性肠病

英夫利西单抗与乌司奴单抗在生物制剂初治克罗恩病中的疗效与起效速度比较

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-07

该事后分析基于2项大型临床试验项目中420例生物制剂初治的中重度克罗恩病患者数据,比较英夫利西单抗与乌司奴单抗诱导治疗的疗效和起效速度。第6周临床缓解率(44.9% vs 37.9%;aOR 1.22;95%CI 0.79-1.89)、临床应答率(58.4% vs 54.9%;aOR 1.25;95%CI 0.82-1.90)及基线钙卫蛋白升高者第6周钙卫蛋白<250 mcg/L的比例(42.3% vs 34.7%;aOR 1.34;95%CI 0.79-2.28)均无显著差异,倾向性评分匹配队列结果相似。

要点

  • 生物制剂初治中重度CD患者中,英夫利西单抗与乌司奴单抗第6周临床缓解和应答率无显著差异。
  • 两种药物第6周实现钙卫蛋白<250 mcg/L的比例亦无显著差异。
  • 倾向性评分匹配队列分析结果与主分析一致,支持两种药物疗效和起效速度相似。

核心结论

  • 基于该事后分析,英夫利西单抗与乌司奴单抗在生物制剂初治克罗恩病患者中疗效和起效速度相似。

研究设计与样本

  • 该研究为对2项大型克罗恩病临床试验项目的事后分析,纳入420例生物制剂初治的克罗恩病患者。
  • 采用多因素logistic回归校正混杂因素,并使用倾向性评分构建匹配队列进行敏感性分析。

主要发现

  • 第6周临床缓解率:英夫利西单抗组44.9% vs 乌司奴单抗组37.9%;校正比值比(aOR)1.22;95%CI 0.79-1.89。
  • 第6周临床应答率:英夫利西单抗组58.4% vs 乌司奴单抗组54.9%;aOR 1.25;95%CI 0.82-1.90。
  • 基线钙卫蛋白升高者第6周钙卫蛋白<250 mcg/L的比例:英夫利西单抗组42.3% vs 乌司奴单抗组34.7%;aOR 1.34;95%CI 0.79-2.28。
  • 倾向性评分匹配队列中各分析结果与主分析相似。

临床怎么用

  • 对于生物制剂初治的中重度克罗恩病患者,英夫利西单抗与乌司奴单抗均可作为诱导治疗选择,两者疗效和起效速度相似。

局限性

  • 该研究为事后分析,结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Comparative effectiveness has become increasingly important to help position therapies for inflammatory bowel disease. We compared the efficacy and rapidity of onset of action of infliximab vs ustekinumab induction therapy for moderate to severe biologic-naïve Crohn's disease (CD) using patient-level data from randomized controlled trials. METHODS: This was a post hoc analysis of 2 large CD clinical trial programs that included data on 420 biologic-naïve CD patients. Differences in proportions of patients achieving week 6 clinical remission, clinical response, and normalization of calprotectin were compared. Multivariate logistic regression was used to adjust for confounders. Sensitivity analysis was conducted using propensity scores to create a cohort of matched participants with similar distribution of baseline covariates. RESULTS: At week 6, a comparable number of patients achieved clinical remission with infliximab compared with patients treated with ustekinumab (44.9% vs 37.9%; adjusted odds ratio [aOR], 1.22; 95% CI, 0.79-1.89). Similarly, at week 6 the clinical response rates were not significantly different (58.4% infliximab vs 54.9% ustekinumab; aOR, 1.25; 95% CI, 0.82-1.90). No significant difference was observed between treatment groups for achieving a week 6 fecal calprotectin level less than 250 mcg/L in those with increased values at baseline (42.3% infliximab vs 34.7% ustekinumab; aOR, 1.34; 95% CI, 0.79-2.28). Similar results were seen for all analyses performed within the propensity matched cohort. CONCLUSIONS: Based on this post hoc analysis, infliximab and ustekinumab appear to have similar efficacy and speed of onset in patients with CD who are biologic-naïve.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Narula N, Wong ECL, Dulai PS, et al. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. Clin Gastroenterol Hepatol. 2021. PMID: 33838348. doi:10.1016/j.cgh.2021.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。